16.11.18

BMH BRÄUTIGAM ADVISES CAPITON ON INVESTMENT IN EURO VITAL PHARMA GMBH

BMH BRÄUTIGAM advised longstanding client capiton AG on the investment in Euro Vital Pharma GmbH. In addition to the contract negotiation, the range of BMH BRÄUTIGAM’s consultancy included the areas of management participation, financing, merger control and warranty / indemnity insurance.

Euro Vital Pharma (EVP), which is based in Hamburg, is a pharmaceutical company and over the last 25 years has become the market leader in the German OTC Private Label Retail market. EVP develops, manufactures and markets healthcare products including pharmaceuticals, medical devices and nutritional supplements. Thanks to its comprehensive product portfolio and own Marketing Authorizations, EVP can support its customers beyond the supply of products in their strategy and development of an own store-brand offering. Customers include all leading drugstore and grocery retailers. Based on its leading market position, capiton is planning to grow the business both organically in Germany and abroad, as well as through targeted acquisitions. BMH BRÄUTIGAM had lately advised capiton on the acquisition of a participation in BWTS, Raith, ISPIN AG as well as on several exits. capiton has experience in the implementation of buy & build concepts, for example the set-up of Schur Flexibles group on which also BMH BRÄUTIGAM was advisor to capiton. Team BMH BRÄUTIGAM: Jan-Peter Heyer, Dr. Sylko Winkler (lead), Dr. Andrea Reichert-Clauss (et al. merger control), Tina Schmidt, Dr. Matthias Rüping (all Private Equity ǀ Corporate/M&A)